PEACCEL
June 22, 2026
Theater 3
Type: Company Presentation
Focus Area:
Tools/Drug Development Support Tech
PEACCEL is a DeepTech company pioneering AI- and Quantum-driven peptide and protein design. Its proprietary innov’SAR platform integrates generative AI, ML, DL, and early Quantum machine learning to engineer high-value biologics with exceptional speed and precision. The company targets two major unmet medical needs: (1) antimicrobial resistance, through therapeutic peptides, and (2) cardio-metabolic disease, via a proprietary cholesterol-clearing peptide — both entering pre-clinical development. Powered by Google Cloud and supported by Synthelis for wet-lab validation, PEACCEL has secured $8.7M+ in non-dilutive funding, filed three global patent families, and demonstrated a quantum advantage up to 14 qubits for drug toxicity prediction. Recognized by NVIDIA as an “AI Start-Up to Watch, PEACCEL is now raising a $50 M Series A to scale its peptide pipeline toward IND readiness and expand its AI-Quantum discovery infrastructure to over 1 billion in-silico molecule evaluations per day.
Company HQ City:
Paris
Company HQ State:
PARIS
Company HQ Country:
France
Year Founded:
2018
Lead Product in Development:
- The company targets two major unmet medical needs: (1) antimicrobial resistance, through therapeutic peptides, and (2) cardio-metabolic disease, via a proprietary cholesterol-clearing peptide — both entering pre-clinical development.
CEO
Prof. Frederic CADET - Founder & Board Chair
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
7
When you expect your next catalyst update?
March 2028
What is your next catalyst (value inflection) update?
Milestones 18-24 months: 2 IND-enabling packages | 3 active platform licenses | 1 drug out-licensing | 4 paid partnerships/programs.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}